The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

No longer 'boutique' Generate is executing, CEO says
Finance

No longer 'boutique' Generate is executing, CEO says

The fund manager is now the seventh-largest KiwiSaver provider.

ANZ half-year profit surges on non-cash gains
Finance

ANZ half-year profit surges on non-cash gains

Cash earnings were flat, and net interest margin rose slightly.

Pattrick Smellie 08 May 2025
BNZ preserves margins on flat half-year
Finance

BNZ preserves margins on flat half-year

BNZ outranks its Australian cousins for customer preference.

Pattrick Smellie 07 May 2025
Westpac's NZ net interest margin expands again
Finance

Westpac's NZ net interest margin expands again

Net interest margins rose in NZ, but shrank for the group as a whole.

Pattrick Smellie 05 May 2025